Abnormal Sphingolipid World in Inflammation Specific for Lysosomal Storage Diseases and Skin Disorders

被引:33
作者
Moskot, Marta [1 ,2 ]
Bochenska, Katarzyna [2 ]
Jakobkiewicz-Banecka, Joanna [2 ]
Banecki, Bogdan [3 ]
Gabig-Ciminska, Magdalena [1 ,2 ]
机构
[1] Polish Acad Sci, Inst Biochem & Biophys, Lab Mol Biol, Kadki 24, PL-80822 Gdansk, Poland
[2] Univ Gdansk, Dept Med Biol & Genet, Wita Stwosza 59, PL-80308 Gdansk, Poland
[3] UG MUG, Intercollegiate Fac Biotechnol, Dept Mol & Cellular Biol, Abrahama 58, PL-80307 Gdansk, Poland
关键词
sphingolipid metabolism alterations; inflammatory diseases; lysosomal storage diseases; skin disorders; treatments; workable therapies; STRATUM-CORNEUM LIPIDS; MITOCHONDRIAL PERMEABILITY TRANSITION; CENTRAL-NERVOUS-SYSTEM; GAUCHER-DISEASE; KRABBE DISEASE; SANDHOFF-DISEASE; FATTY-ACID; EPIDERMAL SPHINGOLIPIDS; SULFATIDE DEFICIENCY; SIGNAL-TRANSDUCTION;
D O I
10.3390/ijms19010247
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Research in recent years has shown that sphingolipids are essential signalling molecules for the proper biological and structural functioning of cells. Long-term studies on the metabolism of sphingolipids have provided evidence for their role in the pathogenesis of a number of diseases. As many inflammatory diseases, such as lysosomal storage disorders and some dermatologic diseases, including psoriasis, atopic dermatitis and ichthyoses, are associated with the altered composition and metabolism of sphingolipids, more studies precisely determining the responsibilities of these compounds for disease states are required to develop novel pharmacological treatment opportunities. It is worth emphasizing that knowledge from the study of inflammatory metabolic diseases and especially the possibility of their treatment may lead to insight into related metabolic pathways, including those involved in the formation of the epidermal barrier and providing new approaches towards workable therapies.
引用
收藏
页数:28
相关论文
共 209 条
[1]  
Aerts JM, 2011, ADV EXP MED BIOL, V721, P99, DOI 10.1007/978-1-4614-0650-1_7
[2]   Alterations of glucosylceramide-β-glucosidase levels in the skin of patients with psoriasis vulgaris [J].
Alessandrini, F ;
Pfister, S ;
Kremmer, E ;
Gerber, JK ;
Ring, J ;
Behrendt, H .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (06) :1030-1036
[3]   The level of prosaposin is decreased in the skin of patients with psoriasis vulgaris [J].
Alessandrini, F ;
Stachowitz, S ;
Ring, J ;
Behrendt, H .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 116 (03) :394-400
[4]  
[Anonymous], HEXOSAMINIDASE DEFIC
[5]   RCeveierwamide and ceramide 1-phosphate in health and disease [J].
Arana, Lide ;
Gangoiti, Patricia ;
Ouro, Alberto ;
Trueba, Miguel ;
Gomez-Munoz, Antonio .
LIPIDS IN HEALTH AND DISEASE, 2010, 9
[6]   Current knowledge on psoriasis and autoimmune diseases [J].
Ayala-Fontanez, Nilmarie ;
Soler, David C. ;
McCormick, Thomas S. .
PSORIASIS-TARGETS AND THERAPY, 2016, 6 :7-32
[7]   Exit Strategies: S1P Signaling and T Cell Migration [J].
Baeyens, Audrey ;
Fang, Victoria ;
Chen, Cynthia ;
Schwab, Susan R. .
TRENDS IN IMMUNOLOGY, 2015, 36 (12) :778-787
[8]  
Barak V, 1999, EUR CYTOKINE NETW, V10, P205
[9]   Bioactive sphingolipids: metabolism and function [J].
Bartke, Nana ;
Hannun, Yusuf A. .
JOURNAL OF LIPID RESEARCH, 2009, 50 :S91-S96
[10]   INOSITOL TRISPHOSPHATE AND DIACYLGLYCEROL AS 2ND MESSENGERS [J].
BERRIDGE, MJ .
BIOCHEMICAL JOURNAL, 1984, 220 (02) :345-360